Skip to main content
OliX Pharmaceuticals, Inc. logo

OliX Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · 226950 ISIN · KR7226950004 KO Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2026-02-26 Director's Dealing
Country KR South Korea
Listing KO 226950

About OliX Pharmaceuticals, Inc.

https://olixpharma.com

OliX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the development of therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric siRNA (asiRNA) platform to create treatments that selectively silence disease-causing genes. Its research and development efforts are focused on building a robust pipeline of drug candidates targeting a variety of illnesses with high unmet medical needs. The pipeline has a particular emphasis on ophthalmic and dermal disorders, with key programs addressing conditions such as hypertrophic scars, age-related macular degeneration (AMD), and other fibrotic and ocular diseases.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. It details specific share transactions (purchases and sales) by an executive (Kim Young-jin) of Olix Co., Ltd. This type of filing is classified as a Director's Dealing (DIRS) as it reports personal share transactions by company insiders.
2026-02-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is specifically used to report insider transactions (share acquisitions or disposals) by company directors or major shareholders. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2026-02-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. It details the shareholding changes of a specific director (Kang Chung-gil) of Olix Co., Ltd. due to the exercise of stock options. This falls under the category of Director's Dealing (insider trading/shareholding report).
2026-02-26 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (OliX) regarding a significant change (over 30%) in revenue or profit structure. This is a standard disclosure requirement in the Korean stock market (KRX) for listed companies to announce preliminary financial results before the final audit report is published. Since it provides key financial highlights (revenue, operating profit, net income) for the fiscal year, it fits the definition of an Earnings Release (ER).
2026-02-12 Korean
기타시장안내 (연구개발 우수기업 매출액 특례적용 관련)
Regulatory Filings Classification · 95% confidence The document is a short announcement from the KOSDAQ market regarding a specific regulatory status (revenue exemption for R&D excellence) for the company Olix. It does not contain full financial statements or a comprehensive report, but rather serves as a formal regulatory notification of a market rule application. As it is a miscellaneous regulatory announcement that does not fit into specific categories like earnings or dividends, it falls under the RNS category.
2026-02-12 Korean
투자판단관련주요경영사항 (중추신경계 전달체 기술평가 및 기술도입 옵션 계약 체결)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (OliX) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details a specific business contract (technology evaluation and licensing option agreement) with a third party (Key2Brain). Since this is a specific corporate announcement regarding a business transaction/agreement that does not fit into the other specialized categories like M&A or share issues, it falls under the general regulatory filing category.
2026-02-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.